OLUMIANT (Eli Lilly Australia Pty Ltd)
Product name
OLUMIANT
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
216 (255 working days)
Active ingredients
baricitinib
Registration type
EOI
Indication
Atopic Dermatitis
OLUMIANT (tablet) is now also indicated for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.